|
| Drug/intervention | Status/paper | Design | N | Follow-up | Population | Author conclusions |
|
| Intravitreal pegaptanib versus sham injections | Cunningham Jr. et al. [28] | Randomized; double masked; Dose-ranging; controlled | 172 | 36 weeks | Center involving DME, VA 20/50–20/320 | Pegaptanib group had better VA, reduction in CRT, and less likely to need photocoagulation at followup |
|
| Intravitreal pegaptanib versus sham injections | Sultan et al. [29] | Randomized; sham controlled; multicenter; parallel group | 260 in year 1 207 in year 2 | 2 years | Center involving DME | Pegaptanib offers clinical benefit for patients with DME: better VA, reduced CRT |
|
| Comparing laser alone, laser with intravitreal triamcinolone, laser with intravitreal ranibizumab, and intravitreal ranibizumab alone | Active, no publication (NCT00444600) | Randomized; double masked; parallel assignment; four treatment arms | 691 | 22 months | Center involving DME | Results not yet published |
|
| ranibizumab versus nontreatment | Massin et al. [30] (RESOLVE) | Randomized; double masked; parallel assignment | 100 | 12 months | Center involving DME | Ranibizumab is effective in improving BCVA and is well tolerated in DME |
|
| Ranibizumab with laser versus laser alone | Mitchell et al. [31] (RESTORE) | Randomized; double Masked; laser controlled; multicenter | 345 | 12 months | Type 1 and 2 diabetic patients with visual impairment due to DME | Combined therapy provided superior VA gain. No difference detected at 1 year |
|
| Ranibizumab versus laser | Active, no publication (LUCIDATE) (NCT01223612) | Randomized; open label; parallel assignment | 40 | 48 weeks | Type 1 and type 2 diabetic patients with DME | Results not yet published |
|
| Intravitreal injection on bevacizumab (4 doses) versus focal photocoagulation | Scott et al. [32] | Randomized; partially masked; five treatment arms | 121 | 24 weeks | Center involving DME | Promising data warranting a phase III trial |
|
| Intravitreal bevacizumab versus triamcinolone | Completed, no publication (NCT01342159) | Randomized; single blind; parallel assignment; three treatment arms | 80 | 20 months | Center involving DME | Results not yet published |
|
| Intravitreal bevacizumab dose comparison | Lam et al. [33] | Randomized; dose ranging | 52 | 62 weeks | Diffuse, center involving DME | Both treatment arms were associated with similar reduced CRT and increased BCVA |
|
| Intravitreal bevacizumab alone or in combination with intravitreal triamcinolone versus macular laser photocoagulation | Soheilian et al. [34] | Randomized; double masked; three treatment arms | 150 | 24 weeks | Clinically significant DME | Bevacizumab arm yielded a better visual outcome versus photocoagulation |
|
